BOBO DONALD E JR 4

What Happened

• Donald E. Bobo Jr., CVP, Strategy & Corporate Development at Edwards Lifesciences, had 13,457 performance-based rights vest on May 11, 2026 and converted those rights into common shares. To cover tax withholding, 7,469 of the vested shares were surrendered/disposed at $79.96 per share, generating a tax withholding value of $597,221. The remaining vested shares were issued to him.

Key Details

• Transaction date: May 11, 2026 (Form 4 filed May 12, 2026 — timely)
• Primary actions reported:
  • Exercise/conversion of derivative (performance rights) into 13,457 shares (code M)
  • Payment of tax liability via withholding/surrender of 7,469 shares at $79.96 each (code F), value $597,221
• Footnotes:
  • F1: These were performance-based awards granted May 11, 2023; the Compensation & Governance Committee certified 167.70% of the target vested as of May 11, 2026 and the actual vested share count is shown.
  • F2: The Performance Rights expire May 10, 2030.
• Shares owned after transaction: Not specified in the filing (Form 4 reflects only the changes shown).
• Filing timeliness: Filed within the required Form 4 window (not indicated as late).

Context

• This was not an open-market sale signaling disposition to a third party: 7,469 shares were withheld/surrendered to cover tax obligations related to the vesting/exercise. Such withholdings are routine when equity awards vest and do not necessarily indicate a change in the insider’s investment view.